Kirk E. Evoy

1.7k total citations · 1 hit paper
48 papers, 1.2k citations indexed

About

Kirk E. Evoy is a scholar working on Public Health, Environmental and Occupational Health, Anesthesiology and Pain Medicine and Emergency Medicine. According to data from OpenAlex, Kirk E. Evoy has authored 48 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Public Health, Environmental and Occupational Health, 12 papers in Anesthesiology and Pain Medicine and 10 papers in Emergency Medicine. Recurrent topics in Kirk E. Evoy's work include Opioid Use Disorder Treatment (21 papers), Pain Management and Opioid Use (7 papers) and Pharmaceutical Practices and Patient Outcomes (7 papers). Kirk E. Evoy is often cited by papers focused on Opioid Use Disorder Treatment (21 papers), Pain Management and Opioid Use (7 papers) and Pharmaceutical Practices and Patient Outcomes (7 papers). Kirk E. Evoy collaborates with scholars based in United States and Russia. Kirk E. Evoy's co-authors include Stephen R. Saklad, Alyssa M. Peckham, Jordan R. Covvey, Leslie Ochs, Lucas G. Hill, Kelly R. Reveles, Steven R. Abel, Corey S. Davis, Kevin Tidgewell and Kathleen A. Fairman and has published in prestigious journals such as JAMA, Addiction and Drugs.

In The Last Decade

Kirk E. Evoy

44 papers receiving 1.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Abuse and Misuse of Pregabalin and Gabapentin

2017 298 citations Kirk E. Evoy et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Kirk E. Evoy United States	18	581	250	211	192	178	48	1.2k
Alyssa M. Peckham United States	19	528 0.9×	259 1.0×	149 0.7×	196 1.0×	144 0.8×	38	1.0k
Gary M. Reisfield United States	20	603 1.0×	321 1.3×	190 0.9×	238 1.2×	63 0.4×	67	1.5k
Jeffrey Gudin United States	18	535 0.9×	396 1.6×	162 0.8×	181 0.9×	58 0.3×	62	1.2k
Joji Suzuki United States	20	775 1.3×	199 0.8×	526 2.5×	213 1.1×	68 0.4×	96	1.8k
Bridin Murnion Australia	19	419 0.7×	256 1.0×	256 1.2×	205 1.1×	278 1.6×	65	1.7k
Shanthi Mogali United States	12	547 0.9×	184 0.7×	308 1.5×	145 0.8×	55 0.3×	18	1.0k
Emily A. Karanges Australia	15	339 0.6×	171 0.7×	92 0.4×	210 1.1×	152 0.9×	30	1.3k
Émilie Jouanjus France	19	389 0.7×	108 0.4×	188 0.9×	174 0.9×	99 0.6×	58	1.1k
James P. Trinidad United States	10	490 0.8×	131 0.5×	246 1.2×	268 1.4×	41 0.2×	14	1.0k
Carl L. Roland United States	17	846 1.5×	642 2.6×	364 1.7×	333 1.7×	69 0.4×	55	1.6k

Countries citing papers authored by Kirk E. Evoy

Since Specialization

Citations

This map shows the geographic impact of Kirk E. Evoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kirk E. Evoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kirk E. Evoy more than expected).

Fields of papers citing papers by Kirk E. Evoy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kirk E. Evoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kirk E. Evoy. The network helps show where Kirk E. Evoy may publish in the future.

Co-authorship network of co-authors of Kirk E. Evoy

This figure shows the co-authorship network connecting the top 25 collaborators of Kirk E. Evoy. A scholar is included among the top collaborators of Kirk E. Evoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kirk E. Evoy. Kirk E. Evoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Evoy, Kirk E., et al.. (2025). The Role of Pharmacists in Mitigating Patient Harms and Drug Misinformation Risks Arising From Synthetic Smoke Shop Products. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 8(11). 1111–1116.

Mathews, Jonathan P., et al.. (2025). Efficacy of Healthcare Student-Led Stop the Bleed Training for Middle School Students. Disaster Medicine and Public Health Preparedness. 19. e71–e71.

Evoy, Kirk E., et al.. (2025). A novel clinical interprofessional education experience between pharmacy and dental students in an advanced geriatric surgical dental clinic. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 8(8). 791–798.

Vadiei, Nina, Kirk E. Evoy, & Oliver Grundmann. (2025). The Impact of Diverse Kratom Products on Use Patterns, Dependence, and Toxicity. Current Psychiatry Reports. 27(10). 584–592. 4 indexed citations

Vadiei, Nina, et al.. (2024). Kratom as a potential substance use disorder harm reduction agent. Frontiers in Public Health. 12. 1416689–1416689. 3 indexed citations

Hill, Lucas G., et al.. (2023). Research and scholarly methods: Audit studies. JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY. 6(5). 521–527. 3 indexed citations

Evoy, Kirk E., et al.. (2023). Quetiapine and olanzapine misuse prevalence in a US general population sample. Mental Health Clinician. 13(2). 25–35. 1 indexed citations

Witry, Matthew J., et al.. (2022). Community pharmacists’ counseling regarding nicotine replacement therapy: A secret shopper study. Journal of the American Pharmacists Association. 63(2). 574–581.e3. 2 indexed citations

Covvey, Jordan R., et al.. (2022). Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse. Research in Social and Administrative Pharmacy. 19(4). 599–609. 4 indexed citations

10.

Teng, Chengwen, et al.. (2022). Retrospective Cohort Evaluating the Comparative Effectiveness of Ceftaroline and Daptomycin as First-Line Therapies for Inpatient Treatment of Diabetic Foot Infection in the United States Veterans Health Care System. Drugs - Real World Outcomes. 9(4). 609–615. 1 indexed citations

11.

Barner, Jamie C., et al.. (2021). Prevalence of and Factors Associated with Gabapentinoid Use and Misuse Among Texas Medicaid Recipients. Clinical Drug Investigation. 41(3). 245–253. 10 indexed citations

12.

Evoy, Kirk E., Jordan R. Covvey, Alyssa M. Peckham, & Kelly R. Reveles. (2021). Gabapentinoid misuse, abuse and non-prescribed obtainment in a United States general population sample. International Journal of Clinical Pharmacy. 43(4). 1055–1064. 22 indexed citations

13.

Evoy, Kirk E., et al.. (2021). Characterization of hospitalized patients who received naloxone while receiving opioids with or without gabapentinoids. Mental Health Clinician. 11(4). 225–230. 6 indexed citations

14.

Evoy, Kirk E., Lucas G. Hill, & Corey S. Davis. (2021). Considering the Potential Benefits of Over-the-Counter Naloxone. PubMed. Volume 10. 13–21. 31 indexed citations

15.

Hill, Lucas G., et al.. (2020). Availability of buprenorphine/naloxone films and naloxone nasal spray in community pharmacies in Texas, USA. Addiction. 116(6). 1505–1511. 49 indexed citations

16.

Evoy, Kirk E., et al.. (2020). Stop the Bleed: An Interprofessional Community Service Learning Project Assessing the Efficacy of Pharmacist-Led Hemorrhage Control Education for Laypersons. Disaster Medicine and Public Health Preparedness. 15(3). 271–276. 6 indexed citations

17.

Evoy, Kirk E., et al.. (2019). A pilot study assessing the addition of a Quit and Winprogram to pharmacist-led intensive smoking cessationtherapy in a predominantly underserved, minority population. Tobacco Prevention & Cessation. 5(November). 44–44. 1 indexed citations

18.

Evoy, Kirk E., et al.. (2018). Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS). Research in Social and Administrative Pharmacy. 15(8). 953–958. 74 indexed citations

19.

Peckham, Alyssa M., Kirk E. Evoy, Leslie Ochs, & Jordan R. Covvey. (2018). Gabapentin for Off-Label Use: Evidence-Based or Cause for Concern?. Substance Abuse Research and Treatment. 12. 620358815–620358815. 75 indexed citations

20.

Evoy, Kirk E., et al.. (2016). Combination bupropion SR and varenicline for smoking cessation: a systematic review. The American Journal of Drug and Alcohol Abuse. 42(2). 129–139. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact